Food and Drug Administration granted Breakthrough Therapy Designation for povetacicept in IgA nephropathy; on track to file for accelerated approval in the U.S. in H1 2026 if 36-week interim analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback